MedPath

TO STUDY EFFECT OF ABHAYADI GHANAWATI COMPARED TO TABLET RANITIDINE IN MANAGEMENT OF URDHVAG AMLAPITTA

Not yet recruiting
Conditions
Acute gastritis,
Registration Number
CTRI/2025/05/086844
Lead Sponsor
SELF
Brief Summary

A Randomised Comparative Clinical Trial will be done and patients will be selected in two groups as per the inclusion criteria

Administration of the drug will be for 30 days for Group A and Group B

Followup will be taken at an interval of 7days for 2 weeks

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
35
Inclusion Criteria

patients having signs and symptoms of urdhvag amlapitta as described in ayurvedic samhitas that is chardi,amlodgar,hrullas,hruda kantadaha,udarda,shirashool,hastapada daha,aruchi,maddalotpatti.

Exclusion Criteria

patients suffering gastric ulcers, duodenal ulcers pregnant and lactating women CA stomach,oesophagus,esophageal varices, hematemesis patients having hepatic and renal disorders immunocompromised patients,blood coagulation systemic diseases like HTN,TB,DM.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
4 weeksABHAYADI GHANAWATI IS EFFECTIVE IN URDHVAG AMLAPITTA
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Research Institute

🇮🇳

Pune, MAHARASHTRA, India

Research Institute
🇮🇳Pune, MAHARASHTRA, India
RUPALI KHOBRAGADE
Principal investigator
08378929859
khobragaderupali19@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.